Influence of postmenopausal hormone replacement therapy on an estrogen metabolite biomarker of risk for breast cancer

Hormone and Metabolic Research

Volumn 35, Issue 6, 2003, Pages 358-361

  Alvarez Vasquez, R B ^a   Axelrod, D ^a   Frenkel, K ^b   Newman, M C ^a   Sepkovic, D W ^c   Bradlow, H L ^c   Zumoff, Barnett ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Breast Cancer; Estrogens; Risk Factors

Indexed keywords

16 ALPHA HYDROXYESTERONE; 2 HYDROXYESTERONE; BIOLOGICAL MARKER; CONJUGATED ESTROGEN; ESTROGEN; MEDROXYPROGESTERONE ACETATE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; METABOLITE; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; URINARY EXCRETION; UTERUS;

BREAST NEOPLASMS; CROSS-SECTIONAL STUDIES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; HYDROXYESTRONES; MEDROXYPROGESTERONE 17-ACETATE; POSTMENOPAUSE; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0042838309     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-41357     Document Type: Article

References (22)

1. Greene RR, Brewer JI. Relation of sex hormones to tumors of the female reproductive system. Am J Roentgenol Radiother 1941; 45: 426-445
2. Colditz GA, Stampfer MJ, Willett WC, Hennekens CH, Rosner B, Speizer FE. Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA 1990; 264: 2648-2653
3. Gapstur SM, Potter JD, Sellers TA, Folsom AR. Increased risk of breast cancer with alcohol consumption in postmenopausal women. Am J Epidemiol 1992; 136: 1221-1231
4. Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, Berkelman RL. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991; 265: 1985-1990
5. Grady D, Ernster V. Invited commentary: does postmenopausal hormone therapy cause breast cancer? Am J Epidemiol 1991; 134: 1396-1400
6. Sillero-Arenas M, Delgado-Rodriguez M, Rodriguez-Conteras R, Bueno-Cavanillas A, Galnez-Vargas R. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol 1992; 79: 286-294
7. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: Results from epidemiological studies. Am J Obstet Gynecol 1993; 168: 1473-1480
8. Dupont WD, Page DL. Therapy and breast cancer. Arch Int Med 1991; 151: 67-72
9. Armstrong BK. Oestrogen therapy after the menopause-boon or bane? Med J Austral 1988; 148: 213-214
10. Gambrell RD Jr. Hormone replacement therapy and breast cancer risk. Arch Fam Med 1996; 5: 341-348
11. Zumoff B. Does postmenopausal estrogen administration increase the risk of breast cancer? Contributions of animal, biochemical, and clinical investigative studies to a resolution of the controversy. Proc Soc Exp Biol Med 1998; 217: 31-37
12. Ginsburg EL, Mello NK, Mendelson JH, Barbieri RL, Teoh SK, Rothman M, Gao X, Sholar JW. Effects of alcohol ingestion on estrogens in postmenopausal women. JAMA 1996; 276: 1747-1751
13. Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favorable histology. JAMA 1999; 281: 2091-2097
14. Writing Group for the Women's Health Institute. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288: 32-33
15. Schneider J, Kinne D, Fracchia A, Pierce V, Anderson KE, Bradlow HL, Fishman J. Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci USA 1982; 79: 3047-3051
16. Bradlow HL, Hershcopf R, Martucci C, Fishman J. 16α-hydroxylation of estradiol: A possible risk marker for breast cancer. Ann NY Acad Sci 1986; 464: 138-151
17. Suto A, Bradlow HL, Kubota T, Kitajima M, Wong GY, Osborne MP, Telang NT. Alteration in proliferative and endocrine responsiveness of human mammary carcinoma cells by prototypic tumor-suppressing agents. Steroids 1993; 58: 215-219
18. Auburn KJ, Woodworth C, DiPaolo JA, Bradlow HL. The interaction between HPV infection and estrogen metabolism in cervical carcinogenesis. Int J Cancer 1991; 49: 867-869
19. Suto A, Bradlow HL, Kubota T, Kitajima M, Wong GY, Osborne MP, Stelang NT. Alteration in proliferative and endocrine responsiveness of human mammary carcinoma cells by prototypic tumor-suppressing agents. Steroids 1993; 58: 215-219
20. Telang NT, Suto A, Wong GY, Osborne MP, Bradlow HL. Estrogen metabolite 16α-hydroxyestrone induces genotoxic damage and aberrant cell proliferation in mouse mammary epithelial cells in culture. J Natl Cancer Inst 1992; 84: 634-638
21. Kabat GC, Chang CJ, Sprano JA, Sepkovic DW, Hu XP, Khalil A, Rosenblatt R, Bradlow HL. Urinary estrogen metabolites and breast cancer. A case-control study. Cancer Epidemiol Biomarkers Preven 1997; 6: 505-509
22. Bradlow HL, Sepkovic DW, Klug T, Osborne MP. Application of an improved ELISA assay to the analysis of urinary estrogen metabolites. Steroids 1998; 63: 406-413